JOURNAL CONTENT
CONTACT

Submission of the manuscript is online via e-mail
ecgarticle@gmail.com or
cholerez@mail.ru

Tel: +7 903 250 5288

Editorial Correspondence e-mail
gastrossr@gmail.com


Publishing, Subscriptions, Sales and Advertising, Correspondence e-mail
journal@cniig.ru

Tel: +7 917 561 9505

THE RULES OF SUBMITTING AN ARTICLE

READ

Scimago Journal & Country Rank

SCImago Journal & Country Rank

LECTION

    1. First Saint Petersburg I. P. Pavlov State Medical University (St. Petersburg, Russian Federation)

    Keywords:hiatal hernia,diagnosis of hiatal hernia,surgical treatment of hiatal hernia

    Abstract:Hiatal hernia is one of the most common variants of anatomical dislocation of the abdominal cavity elements. The diagnosis of this condition is based on the results of endoscopic and radiologic investigations. Indications for surgical treatment of hiatal hernias are resistance of gastroesophageal reflux symptoms for conservative management and the risk of its infringement. To increase the effectiveness of surgical interventions, prosthetic materials are used to correct of hiatal hole. The type of antireflux reconstruction depends on the gastroesophageal reflux severity and esophageal motility. Good long-term results of surgical treatment of hiatal hernias are found in 75-85 % of cases.

      1. Кубышкин В., Корняк Б. Гастроэзофагеальная рефлюксная болезнь // M.: СПРОС, 1999. - 208 с.
      2. Пучков К., Филимонов В. Грыжи пищеводного отверстия диафрагмы // М.: Медпрактика, 2003. - 171 с.
      3. Granderath F., Kamolz T., Pointner R. Gastroesophageal reflux disease // Springer-Verlag. - Wien., 2006. - 320 p.
      4. Василевский Д., Кулагин В. Хирургическое лечение гастроэзофагеальной рефлюксной болезни (под ред. С. Ф. Багненко) // М.: СИМК, 2015. - 216 с.
      5. Broeders J. Laparoscopic antireflux surgery indications, techniques and physiological effects // Gildeprint Drukkerijen. - Netherlands., 2011. - 350 p.
      6. Katz P., Gerson L., Vela M. Guidelines for the diagnosis and management of gastroesophageal reflux disease // Am. J. Gastroenterol. - 2013. - Vol. 108. - P. 308-328.
      7. Kohn G., Price R., DeMeester S., et al. Guidelines for the management of hiatal hernia // Surg. Endosc. - 2013. - P. 1-42.
      8. Stefanidis D., Hope W., Kohn G. et al. Guidelines for surgical treatment of gastroesophageal reflux disease // Surg. Endoscop. - 2010. - Vol. 24. - P. 2647-2669.
      9. Fei L., del Genio G., Rossetti G., et al. Hiatal hernia recurrence: surgical complication or disease? Electron microscope findings of the diaphragmatic pillars // J. Gastrointest. Surg. - 2009. - Vol. 13. - P. 459-464.
      10. Frantzides C., Carlson M., Loizides S. et al. Hiatal hernia repair with mesh: a survey of SAGES members // Surg. Endosc. - 2010. - Vol. 24. - P. 1017-1024.
      11. Granderath F., Granderath U., Pointner R. Laparoscopic revisional fundoplication with circular hiatal mesh prosthesis: the long-term results // W. J. Surg. - 2008. - Vol. 32. - P. 999-1007.
      12. Pointner R., Granderath F. Hiatus hernia and recurrence: the Achilles heel of antireflux surgery? // Chirurg. - 2008. - Vol. 79. - P. 974-981.
     


    Full text is published :
    Vasilevskiy D.I., Smirnov A.A. DIAGNOSIS AND TREATMENT OF HIATAL HERNIAS. Experimental and Clinical Gastroenterology Journal. 2017;140(04):92-94
    Read & Download full text

    1. Multidisciplinary clinical and diagnostic center “Avicenna” (Simferopol, Russian Federation)

    Abstract:The aim was to study the quality of oral colon preparation for colonoscopy with an individual approach, comparing full volume 4 l of glycols with polyethylene glycols (PEG) of a reduced 2 l volume (MOVIPREP®) under conditions of risk factors for poor bowel preparation. Conclusion: MOVIPREP® has a one-step morning dosage regimen and may be the drug of choice for patients for whom preparation on the day of a colonoscopy is important. MOVIPREP® was noted by patients as more comfortable due to taste, smaller volume, fewer bowel movements, which allows reduction of the time interval between the end of preparation and the holding of a colonoscopy. Keywords: colonoscopy, preparation for colonoscopy, colorectal cancer screening, oral colon cleansers, low-fiber diet, MOVIPREP®, PEG 4 liters

      1. Baxter NN, Goldwasser MA, Paszat LF, et al. Association of colonoscopy and death from colorectal cancer. Ann Intern Med 2009;150:1-8
      2. Rex DK, Johnson DA, Anderson JC, et al. American College of Gastroenterology guidelines for colorectal cancer screening 2008. Am J Gastroenterol 2009;104:739-50.
      3. Levin B, Lieberman DA, McFarland B, et al. Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps, 2008: a joint guideline from the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology. Gastroenterology 2008;134:1570-95
      4. Lieberman DA, Weiss DG, Bond JH, et al. Use of colonoscopy to screen asymptomatic adults for colorectal cancer. Veterans Affairs Cooperative Study Group 380. N Engl J Med 2000;343:162-8.
      5. Imperiale T, Wagner D, Lin C, et al. Risk of advanced proximal neoplasms in asymptomatic adults according to the distal colorectal findings. N Engl J Med 2000;343:169-74.
      6. Kim DH, Lee SY, Choi KS, et al. The usefulness of colonoscopy as a screening test for detecting colorectal polyps. Hepatogastroenterology 2007;54:2240-2.
      7. Niv Y, Hazazi R, Levi Z, et al. Screening colonoscopy for colorectal cancer in asymptomatic people: a meta-analysis. Dig Dis Sci 2008;53: 3049-54.
      8. Emura F, Saito Y, Taniguchi M et al. Further validation of magnifying chromocolonoscopy for differentiating colorectal neoplastic polyps in a health screening center. J Gastroenterol Hepatol 2007; 22: 1722-1727
      9. S. E. Kudo, S. Tamura, T. Nakajima, H. O. Yamano, H. Kusaka, and H. Watanabe. “Diagnosis of colorectal tumorous lesions by magnifying endoscopy,” Gastrointestinal Endoscopy, vol. 44, no. 1, pp. 8-14, 1996.
      10. K. Togashi, F. Konishi, T. Ishizuka, T. Sato, S. Senba, and K. Kanazawa. “Efficacy of magnifying endoscopy in the differential diagnosis of neoplastic and non-neoplastic polyps of the large bowel,” Diseases of the Colon and Rectum, vol. 42, no. 12, pp. 1602-1608, 1999.
      11. Rex DK. Narrow-band imaging without optical magnification for histologic analysis of colorectal polyps. Gastroenterology 2009;136:1174-81
      12. Y. Sano, M. Kobayashi, Y. Hamamoto et al. “New diagnostic method based on color imaging using narrow band imaging (NBI) system for gastrointestinal tract,” Gastrointestinal Endoscopy, vol. 53, p. AB 125, 2001.
      13. K. Gono, K. Yamazaki, N. Doguchi et al. “Endoscopic observation of tissue by narrow-band illumination,” Optical Review, vol. 10, pp. 1-5, 2003.
      14. K. Gono, T. Obi, M. Yamaguchi et al. “Appearance of enhanced tissue features in narrow-band endoscopic imaging,” Journal of Biomedical Optics, vol. 9, no. 3, pp. 568-577, 2004.
      15. Kahi CJ, Anderson JC, Waxman I, et al. High-definition chromocolonoscopy vs. high-definition white light colonoscopy for average-risk colorectal cancer screening. Am J Gastroenterol 2010;105:1301-7.
      16. Pohl J, Schneider A, Vogell H, et al. Pancolonic chromoendoscopy with indigo carmine versus standard colonoscopy for detection of neoplastic lesions: a randomised two-centre trial. Gut 2011;60:485-90
      17. R. Kiesslich, M. Von Bergh, M. Hahn, G. Hermann, and M. Jung. “Chromoendoscopy with indigocarmine improves the detection of adenomatous and nonadenomatous lesions in the colon,” Endoscopy, vol. 33, no. 12, pp. 1001-1006, 2001.
      18. J. C. Brooker, B. P. Saunders, S. G. Shah et al. “Total colonic dye-spray increases the detection of diminutive adenomas during routine colonoscopy: a randomized controlled trial,” Gastrointestinal Endoscopy, vol. 56, no. 3, pp. 333-338, 2002.
      19. H. Mitooka, T. Fujimori, S. Maeda, and K. Nagasako. “Minute flat depressed neoplastic lesions of the colon detected by contrast chromoscopy using an indigo carmine capsule,” Gastrointestinal Endoscopy, vol. 41, no. 5, pp. 453-459, 1995.
      20. K. I. Fu, Y. Sano, S. Kato et al. “Chromoendoscopy using indigo carmine dye spraying with magnifying observation is the most reliable method for differential diagnosis between non-neoplastic and neoplastic colorectal lesions: a prospective study,” Endoscopy, vol. 36, no. 12, pp. 1089-1093, 2004.
      21. Y. Sano, H. Ikematsu, K. I. Fu et al. “Meshed capillary vessels by use of narrow-band imaging for differential diagnosis of small colorectal polyps,” Gastrointestinal Endoscopy, vol. 69, no. 2, pp. 278-283, 2009.
      22. T. Uraoka, Y. Saito, H. Ikematsu, K. Yamamoto, and Y. Sano. “Sano’s capillary pattern classification for narrow-band imaging of early colorectal lesions,” Digestive Endoscopy, vol. 23, supplement 1, pp. 112-115, 2011.
      23. Hassan C, Pickhardt PJ, Rex DK. A resect and discard strategy would improve cost-effectiveness of colorectal cancer screening. Clin Gastroenterol Hepatol 2010; 8: 865-869
      24. Rex DK, Petrini JL, Baron TH, et al. Quality indicators for colonoscopy. Am J Gastroenterol 2006;101: 873-85.
      25. Corley DA, Jensen CD, Marks AR. Can we improve adenoma detection rates? A systematic review of intervention studies. Gastrointest Endosc 2011;74:656-65
      26. Corley D, Jensen CD, Marks AR, et al. Adenoma detection rate and risk of colorectal cancer and death. N Engl J Med 2014;370: 1298-306.
      27. Francis DL, Rodriguez-Correa DT, Buchner A, et al. Application of a conversion factor to estimate the adenoma detection rate from the polyp detection rate. Gastrointest Endosc 2011; 73: 493-7
      28. Rex DK. Colonoscopic withdrawal technique is associated with adenoma miss rates. Gastrointest Endosc 2000; 51: 33-6.
      29. Lee RH, Tang RS, Muthusamy VR, et al. Quality of colonoscopy withdrawal technique and variability in adenoma detection rates (with videos). Gastrointest Endosc 2011; 74: 128-34.
      30. Barclay R, Vicari JJ, Johanson JF, et al. Variation in adenoma detection rates and colonoscopic withdrawal times during screening colonoscopy [abstract]. Gastrointest Endosc 2005;61: AB 107
      31. Barclay RL, Vicari JJ, Doughty AS, et al. Colonoscopic withdrawal times and adenoma detection during screening colonoscopy. N Engl J Med 2006; 355: 2533-41.
      32. Barclay RL, Vicari JJ, Greenlaw RL. Effect of a time-dependent colonoscopic withdrawal protocol on adenoma detection during screening colonoscopy. Clin Gastroenterol Hepatol 2008; 6: 1091-8.
      33. Rex DK. Still photography versus videotaping for documentation of cecal intubation: a prospective study. Gastrointest Endosc 2000; 51: 451-9.
      34. Rex DK, Hewett DG, Raghavendra M, et al. The impact of videorecording on the quality of colonoscopy performance: a pilot study. Am J Gastroenterol 2010;105: 2312-7.
      35. Farrar W, Sawhney M, Nelson D et al. Colorectal cancers found after a complete colonoscopy. Clin Gastroenterol Hepatol 2006; 4: 1259-1264
      36. Robertson DJ, Greenberg ER, Beach M et al. Colorectal cancer in patients under close colonoscopic surveillance. Gastroenterology 2005; 129: 34-41
      37. Sawhney MS, Farrar WD, Gudiseva S et al. Microsatellite instability in interval colon cancers. Gastroenterology 2006; 131: 1700-1705
      38. Bressler B, Paszat L, Chen Z et al. Rates of new or missed colorectal cancers after colonoscopy and their risk. Gastroenterology 2007; 132: 96-102
      39. Singh H, Turner D, Xue L et al. Risk of developing colorectal cancer following a negative colonoscopy examination. JAMA 2006; 295: 2366-2373
      40. Brenner H, Chang-Claude J, Seiler CM, et al. Does a negative screening colonoscopy ever need to be repeated? Gut 2006;55: 1145-50.
      41. Lakoff J, Paszat LF, Saskin R, et al. Risk of developing proximal versus distal colorectal cancer after a negative colonoscopy: a populationbased study. Clin Gastroenterol Hepatol 2008;6: 1117-21.
      42. Singh H, Nugent Z, Mahmud SM, et al. Predictors of colorectal cancer after negative colonoscopy: a population-based study. Am J Gastroenterol 2010;105: 663-73.
      43. Thomas-Gibson S, Rogers P, Cooper S et al. Judgement of the quality of bowel preparation at screening flexible sigmoidoscopy is associated with variability in adenoma detection rates. Endoscopy 2006; 38: 456-460
      44. Harewood GC, Sharma VK, de Garmo P. Impact of colonoscopy preparation quality on detection of suspected colonic neoplasia. Gastrointest Endosc 2003; 58: 76-79
      45. Froehlich F, Wietlisbach V, Gonvers JJ et al. Impact of colonic cleansing on quality and diagnostic yield of colonoscopy: the European Panel of Appropriateness of Gastrointestinal Endoscopy European multicenter study. Gastrointest Endosc 2005; 61: 378-384
      46. Singh H, Nugent Z, Demers AA, et al. The reduction in colorectal cancer mortality after colonoscopy varies by site of the cancer. Gastroenterology 2010;139: 1128-37.
      47. Brenner H, Chang-Claude J, Seiler CM, et al. Protection from colorectal cancer after colonoscopy: a population-based, case-control study. Ann Intern Med 2011;154: 22-30.
      48. Burke CA, Church JM. Enhancing the quality of colonoscopy: the importance of bowel purgatives. Gastrointest Endosc 2007; 66: 565-573
      49. Wexner SD, Beck DE, Baron TH, et al. A consensus document on bowel preparation before colonoscopy: prepared by a Task Force from the American Society of Colon and Rectal Surgeons (ASCRS), the American Society for Gastrointestinal Endoscopy (ASGE), and the Society of American Gastrointestinal and Endoscopic Surgeons (SAGES). Surg Endosc 2006;20: 1161.
      50. Larsen M, Hills N, Terdiman J. The impact of the quality of colon preparation on follow-up colonoscopy recommendations. Am J Gastroenterol 2011;106: 2058-62.
      51. Hassan C et al. Bowel preparation for colonoscopy: ESGE Guideline… Endoscopy 2013; 45: 142-150
      52. Bowel preparation before colonoscopy Gastrointest Endosc 2015;81:781-794 / DOI: http://dx.doi.org/10.1016/j.gie.2014.09.04
      53. Brenner H, Chang-Claude J, Seiler CM, et al. Does a negative screening colonoscopy ever need to be repeated? Gut 2006;55: 1145-50.
      54. Calderwood AH, Jacobson BC. Comprehensive validation of the Boston Bowel Preparation Scale. Gastrointest Endosc 2010;72: 686-92.
      55. B. Rembacken, C. Hassan, J. F. Riemann, A. Chilton, M. Rutter, J.-M. Dumonceau, M. Omar, T. Ponchon. Quality in screening colonoscopy: position statement of the European Society of Gastrointestinal Endoscopy (ESGE). Endoscopy 2012; 44: 957-968
     


    Full text is published :
    Korneev A.A. PREPARING FOR A COLONOSCOPY. CRIMEAN EXPERIENCE. Experimental and Clinical Gastroenterology Journal. 2017;140(04):95-102
    Read & Download full text

    1. Moscow state medical and dentistry University n.a. A.I. Evdokimov (Moscow, Russian Federation)

    Keywords:Helicobacter pylori, eradication therapy, resistance

    Abstract:In accordance with modern consensus recommendations, the choice of eradication therapy (ET) should be based on information about the prevalence of resistant H. pylori strains to clarithromycin and metronidozole (including dual resistance to these drugs) in a particular region of the world. In regions with a low level of clarithromycin resistance (<15%), classical triple therapy is considered as first-line therapy and can be administered empirically. Bismuth-containing quadrotherapy is an alternative. In regions with high resistance to clarithromycin (> 15%), bismuth-containing quadrotherapy or quadrotherapy without bismuth preparations (“simultaneous” therapy) is recommended. In regions with a high double resistance rate, both clarithromycin and metronidazole, bismuth-containing quadrotherapy is recommended as first-line ET. Among the optimization methods that can significantly increase the effectiveness of ET can be distinguished: the addition of bismuth drug in the ET regimen (by 10–20%), the use of rebathide in the ET regimen (by 11.9%), the use of adjuvant therapy using probiotics 8.1–14.1%) and the use of double doses of proton pump inhibitors (by 8%), as well as an increase in patient compliance, timely monitoring of the effectiveness of therapy and the use of adequate doses of drugs with proven effectiveness. Significant reduction in the frequency of adverse events against the background of ongoing ET is achieved only using adjuvant therapy with probiotics.

      1. Маев И. В., Самсонов А. А., Андреев Д. Н. Инфекция Helicobacter pylori. М.: ГЭОТАР-Медиа; 2016.
      2. Morgan D.R, Crowe S. E. Helicobacter pylori infection. In.: Sleisenger and Fordtran’s Gastrointestinal and Liver Disease: Pathophysiology, Diagnosis, Management / edited by Mark Feldman, Lawrence S Friedman, Laurence J Brandt. - 10th ed. 2015.
      3. Malfertheiner P, Megraud F, O’Morain CA, Gisbert JP, Kuipers EJ, Axon AT, Bazzoli F, Gasbarrini A, Atherton J, Graham DY, Hunt R, Moayyedi P, Rokkas T, Rugge M, Selgrad M, Suerbaum S, Sugano K, El-Omar EM. Management of Helicobacter pylori infection-the Maastricht V/Florence Consensus Report. Gut. 2017; 66(1):6-30
      4. Маев И. В., Андреев Д. Н., Кучерявый Ю. А. Инфекция Helicobacter pylori и экстрагастродуоденальные заболевания. Терапевтический архив. 2015; 8: 103-110.
      5. Kyburz A, Müller A. Helicobacter pylori and Extragastric Diseases. Curr Top Microbiol Immunol. 2017;400:325-347.
      6. Sugano K, Tack J, Kuipers EJ, Graham DY, El-Omar EM, Miura S, Haruma K, Asaka M, Uemura N, Malfertheiner P; faculty members of Kyoto Global Consensus Conference. Kyoto global consensus report on Helicobacter pylori gastritis. Gut. 2015; 64(9):1353-67.
      7. Fallone CA, Chiba N, van Zanten SV, Fischbach L, Gisbert JP, Hunt RH, Jones NL, Render C, Leontiadis GI, Moayyedi P, Marshall JK. The Toronto Consensus for the Treatment of Helicobacter pylori Infection in Adults. Gastroenterology. 2016;151(1):51-69.e14
      8. Chey WD, Leontiadis GI, Howden CW, Moss SF. ACG Clinical Guideline: Treatment of Helicobacter pylori Infection. Am J Gastroenterol. 2017;112(2):212-239.
      9. Malfertheiner P, Link A, Selgrad M. Helicobacter pylori: perspectives and time trends. Nat Rev Gastroenterol Hepatol. 2014;11(10):628-38.
      10. Graham DY, Lee YC, Wu MS. Rational Helicobacter pylori therapy: evidence-based medicine rather than medicine-based evidence. Clin Gastroenterol Hepatol 2014;12:177-86.
      11. Feng L, Wen MY, Zhu YJ, Men RT, Yang L. Sequential Therapy or Standard Triple Therapy for Helicobacter pylori Infection: An Updated Systematic Review. Am J Ther. 2016;23(3): e880-93.
      12. Venerito M, Krieger T, Ecker T, Leandro G, Malfertheiner P. Meta-analysis of bismuth quadruple therapy versus clarithromycin triple therapy for empiric primary treatment of Helicobacter pylori infection. Digestion. 2013;88(1):33-45.
      13. Puig I, Baylina M, Sánchez-Delgado J, et al. Systematic review and meta-analysis: triple therapy combining a proton-pump inhibitor, amoxicillin and metronidazole for Helicobacter pylori first-line treatment. J Antimicrob Chemother. 2016;71(10):2740-53.
      14. Li BZ, Threapleton DE, Wang JY, et al. Comparative effectiveness and tolerance of treatments for Helicobacter pylori: systematic review and network meta-analysis. BMJ. 2015;351: h4052.
      15. Lee JY, Park KS. Optimal First-Line Treatment for Helicobacter pylori Infection: Recent Strategies. Gastroenterol Res Pract. 2016;2016:9086581.
      16. Luther J, Higgins PD, Schoenfeld PS, Moayyedi P, Vakil N, Chey WD. Empiric quadruple vs. triple therapy for primary treatment of Helicobacter pylori infection: Systematic review and meta-analysis of efficacy and tolerability. Am J Gastroenterol. 2010;105(1):65-73.
      17. Ermis F, Senocak Tasci E. Current Helicobacter pylori treatment in 2014. World J Methodol. 2015;5(2):101-7.
      18. Essa AS, Kramer JR, Graham DY, Treiber G. Meta-analysis: four-drug, three-antibiotic, non-bismuth-containing “concomitant therapy” versus triple therapy for Helicobacter pylori eradication. Helicobacter. 2009;14(2):109-18.
      19. Gisbert JP, Calvet X. Update on non-bismuth quadruple (concomitant) therapy for eradication of Helicobacter pylori. Clin Exp Gastroenterol. 2012;5:23-34.
      20. He L, Deng T, Luo H. Meta-analysis of sequential, concomitant and hybrid therapy for Helicobacter pylori eradication. Intern Med. 2015;54(7):703-10
      21. Самсонов А. А., Андреев Д. Н., Гречушников В. Б., Айвазова Р. А. Резистентность Helicobacter pylori к компонентам эрадикационной терапии и пути ее преодоления. Фарматека. 2015. 2. С. 26-30.
      22. Gisbert JP, Calvet X, O’Connor JP, Mégraud F, O’Morain CA. The sequential therapy regimen for Helicobacter pylori eradication. Expert Opin Pharmacother.2010;11:905-18.
      23. Vaira D, Zullo A, Hassan C, Fiorini G, Vakil N. Sequential therapy for Helicobacter pylori eradication: The time is now! Therap Adv Gastroenterol. 2009;2:317-22.
      24. Zullo A, De Francesco V, Hassan C, Morini S, Vaira D. The sequential therapy regimen for Helicobacter pylori eradication: A pooled-data analysis. Gut.2007;56:1353-7.
      25. Gatta L, Vakil N, Vaira D, Scarpignato C. Global eradication rates for Helicobacter pylori infection: systematic review and meta-analysis of sequential therapy. BMJ. 2013;347: f4587.
      26. Chen PY, Wu MS, Chen CY, et al. Systematic review with meta-analysis: the efficacy of levofloxacin triple therapy as the first- or second-line treatments of Helicobacter pylori infection. Aliment Pharmacol Ther. 2016;44(5):427-37.
      27. Юренев Г. Л., Андреев Д. Н., Парцваниа-Виноградова Е.В., Дичева Д. Т. Гибридная схема эрадикационной терапии инфекции Helicobacter pylori: систематизация литературных данных. Фарматека. 2017; 2: 71-74.
      28. Song ZQ, Liu J, Zhou LY. Hybrid Therapy Regimen for Helicobacter Pylori Eradication. Chin Med J (Engl). 2016;129(8):992-9.
      29. Hsu PI, Lin PC, Graham DY. Hybrid therapy for Helicobacter pylori infection: A systemic review and meta-analysis. World J Gastroenterol. 2015;21(45):12954-62.
      30. Song ZQ, Zhou LY. Hybrid, sequential and concomitant therapies for Helicobacter pylori eradication: A systematic review and meta-analysis. World J Gastroenterol. 2016;22(19):4766-75.
      31. Андреев Д. Н., Дичева Д. Т., Маев И. В. Возможности оптимизации эрадикационной терапии инфекции Helicobacter pylori в современной клинической практике. Терапевтический архив. 2017; 2: 76-83.
      32. Villoria A., Garcia P., Calvet X., Gisbert J. P., Vergara M. Meta-analysis: high-dose proton pump inhibitors vs. standard dose in triple therapy for Helicobacter pylori eradication // Aliment Pharmacol Ther. 2008; 28 (7): 868-877.
      33. McNicholl AG, Linares PM, Nyssen OP, Calvet X, Gisbert JP. Meta-analysis: esomeprazole or rabeprazole vs. first-generation pump inhibitors in the treatment of Helicobacter pylori infection. Aliment Pharmacol Ther. 2012; 36 (5): 414-425.
      34. Desta ZX, Shin JG, Flockhart DA. Clinical significance of the cytochrome P450 2C 19 genetic polymorphism. Clin. Pharmacokinet. 2002; 41(12): 913-958.
      35. Maev I. V., Andreev D. N., Kucheryavyi Yu.A., Dicheva D. T. Host factors influencing the eradication rate of Helicobacter pylori. World Applied Sci J. 2014; 30: 134-140.
      36. Li-Wan-Po A, Girard T, Farndon P, Cooley C, Lithgow J. Pharmacogenetics of CYP2C 19: functional and clinical implications of a new variant CYP2C 19*17. Br J Clin Pharmacol. 2010;69(3):222-30.
      37. Kuo CH, Lu CY, Shih HY, Liu CJ, Wu MC, Hu HM, Hsu WH, Yu FJ, Wu DC, Kuo FC. CYP2C 19 polymorphism influences Helicobacter pylori eradication. World J Gastroenterol. 2014;20(43):16029-36.
      38. Padol S, Yuan Y, Thabane M, Padol IT, Hunt RH. The effect of CYP2C 19 polymorphisms on H. pylori eradication rate in dual and triple first-line PPI therapies: a meta-analysis. Am J Gastroenterol. 2006;101(7):1467-75.
      39. Sakai T, Aoyama N, Kita T, Sakaeda T, Nishiguchi K, Nishitora Y, Hohda T, Sirasaka D, Tamura T, Tanigawara Y, Kasuga M, Okumura K. CYP2C 19 genotype and pharmacokinetics of three proton pump inhibitors in healthy subjects. Pharm Res. 2001;18(6):721-7.
      40. Gibbons TE, Gold BD. The use of proton pump inhibitors in children: a comprehensive review. Paediatr Drugs. 2003;5(1):25-40.
      41. Litalien C, Théorêt Y, Faure C. Pharmacokinetics of proton pump inhibitors in children. Clin Pharmacokinet. 2005;44(5):441-66.
      42. Tang HL, Li Y, Hu YF, Xie HG, Zhai SD. Effects of CYP2C 19 loss-of-function variants on the eradication of H. pylori infection in patients treated with proton pump inhibitor-based triple therapy regimens: a meta-analysis of randomized clinical trials. PLoS One 2013;8: e62162.
      43. Denisenko NP, Sychev DA, Sizova ZhM, Grachev AV, Velikolug KA. High frequency of CYP2C 19 ultrarapid metabolizers in Russian patients with peptic ulcer. Eksp Klin Gastroenterol. 2015;(6):11-5.
      44. Tsutsui N, Taneike I, Ohara T, Goshi S, Kojio S, Iwakura N, Matsumaru H, Wakisaka-Saito N, Zhang HM, Yamamoto T. A novel action of the proton pump inhibitor rabeprazole and its thioether derivative against the motility of Helicobacter pylori. Antimicrob Agents Chemother. 2000;44(11):3069-73.
      45. Ohara T, Goshi S, Taneike I, Tamura Y, Zhang HM, Yamamoto T. Inhibitory action of a novel proton pump inhibitor, rabeprazole, and its thioether derivative against the growth and motility of clarithromycin-resistant Helicobacter pylori. Helicobacter. 2001;6(2):125-9.
      46. Zhang Z, Liu ZQ, Zheng PY, Tang FA, Yang PC. Influence of efflux pump inhibitors on the multidrug resistance of Helicobacter pylori. World J Gastroenterol. 2010;16(10):1279-84.
      47. Sugimoto M, Sahara S, Ichikawa H, Kagami T, Ban H, Otsuka T, Andoh A, Furuta T. Four-times-daily Dosing of Rabeprazole with Sitafloxacin, High-Dose Amoxicillin, or Both for Metronidazole-Resistant Infection with Helicobacter pylori in Japan. Helicobacter. 2017;22(1). e12319.
      48. Маев И. В., Андреев Д. Н., Дичева Д. Т. Гастропатии, индуцированные нестероидными противовоспалительными средствами: патогенетически обоснованные подходы к профилактике и терапии. Фарматека. 2016; 2: 49-54.
      49. Huang JQ, Sridhar S, Hunt RH. Role of Helicobacter pylori infection and non-steroidal anti-inflammatory drugs in peptic-ulcer disease: a meta-analysis. Lancet. 2002;359(9300):14-22.
      50. Niv Y. Helicobacter pylori and gastric mucin expression: A systematic review and meta-analysis. World J Gastroenterol. 2015;21(31):9430-6.
      51. Ивашкин В. Т., Маев И. В., Ивашкин К. В., Корочанская Н. В., Лопина О. Д., Лапина Т. Л., Полуэктова Е. А., Румянцева Д. Е., Симаненков В. И., Трухманов А. С., Хлынов И. Б., Шептулин А. А. Роль нарушения защитных факторов в развитии кислотозависимых заболеваний. (Резолюция Экспертного совета 12-13 марта 2016). Рос. журн. гастроэнтерол. гепатол. колопроктол. 2016; 26(3):115-116.
      52. Skoczylas T, Sarosiek I, Sostarich S, McElhinney C, Durham S, Sarosiek J. Significant enhancement of gastric mucin content after rabeprazole administration: its potential clinical significance in acid-related disorders. Dig Dis Sci. 2003;48(2):322-8.
      53. Sarosiek I, Olyaee M, Majewski M, Sidorenko E, Roeser K, Sostarich S, Wallner G, Sarosiek J. Significant increase of esophageal mucin secretion in patients with reflux esophagitis after healing with rabeprazole: its esophagoprotective potential. Dig Dis Sci. 2009;54(10):2137-42.
      54. Ge R., Chen Z., Zhou Q. The actions of bismuth in the treatment of Helicobacter pylori infections: an update. Metallomics. 2012; 4 (3): 239-243.
      55. Alkim H, Koksal AR, Boga S, Sen I, Alkim C. Role of Bismuth in the Eradication of Helicobacter pylori. Am J Ther. 2016 Jan 21. [Epub ahead of print].
      56. Dore MP, Lu H, Graham DY. Role of bismuth in improving Helicobacter pylori eradication with triple therapy. Gut. 2016;65(5):870-8.
      57. Liao J, Zheng Q, Liang X, Zhang W, Sun Q, Liu W, Xiao S, Graham DY, Lu H. Effect of fluoroquinolone resistance on 14-day levofloxacin triple and triple plus bismuth quadruple therapy. Helicobacter 2013;18:373-7.
      58. Cao Z, Chen Q, Zhang W, Liang X, Liao J, Liu W, Xiao S, Lu H. Fourteen-day optimized levofloxacin-based therapy versus classical quadruple therapy for Helicobacter pylori treatment failures: a randomized clinical trial. Scand J Gastroenterol. 2015;50(10):1185-90.
      59. Маев И. В., Самсонов А. А., Коровина Т. И. Гречушников В. Б., Андреев Н. Г. Висмута трикалия дицитрат повышает эффективность антихеликобактерной терапии первой линии. Эксперимент. и клин. гастроэнтерол. 2012; 8: 92-97.
      60. Бордин Д. С., Машарова А. А., Хомерики С. Г. Хронический гастрит: современный взгляд на старую проблему. Эксперимент. и клин. гастроэнтерол. 2012; 5: 99-106.
      61. Nishizawa T, Nishizawa Y, Yahagi N, Kanai T, Takahashi M, Suzuki H. Effect of supplementation with rebamipide for Helicobacter pylori eradication therapy: a systematic review and meta-analysis. J Gastroenterol Hepatol. 2014;29 Suppl 4:20-4.
      62. Zou J., Dong J., Yu X. Meta-analysis: Lactobacillus containing quadruple therapy versus standard triple first-line therapy for Helicobacter pylori eradication. Helicobacter. 2009; 14 (5): 97-107.
      63. Szajewska H., Horvath A., Piwowarczyk A. Meta-analysis: the effects of Saccharomyces boulardii supplementation on Helicobacter pylori eradication rates and side effects during treatment. Aliment Pharmacol Ther. 2010; 32 (9): 1069-1079.
      64. Wang Z. H., Gao Q. Y., Fang J. Y. Meta-Analysis of the Efficacy and safety of Lactobacillus-containing and Bifidobacterium-containing probiotic compound preparation in Helicobacter pylori eradication therapy. J Clin Gastroenterol. 2013; 47 (1): 25-32.
      65. Lv Z, Wang B, Zhou X, Wang F, Xie Y, Zheng H, Lv N. Efficacy and safety of probiotics as adjuvant agents for Helicobacter pylori infection: A meta-analysis. Exp Ther Med. 2015; 9(3):707-716.
      66. Lau CS, Ward A, Chamberlain RS. Probiotics improve the efficacy of standard triple therapy in the eradication of Helicobacter pylori: a meta-analysis. Infect Drug Resist. 2016;9:275-289.
      67. Ивашкин В.Т, Лапина Т.Л, Страчунский Л. С., Захарова Н.В, Николаева Н. Н., Ткачев А. В., Симаненков В. И., Абдулхаков Р. А., Осипенко М. Ф., Дехнич Н. Н. Ведение больных язвенной болезнью в амбулаторно-поликлинических условиях: результаты многоцентрового российского фармакоэпидемиологического исследования. Российский журнал гастроэнтерологии, гепатологии, колопроктологии, 2005.6; 16-21.
      68. Маев И. В., Кучерявый Ю. А., Андреев Д. Н. Причины неэффективности антигеликобактерной терапии. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2013; 6: 62-72.
      69. Tschabitscher D., Platzer P., Baumgärtel C., Müllner M. Generic drugs: quality, efficacy, safety and interchangeability. Wien. Klin. Wochenschr. 2008; 120 (3-4): 63-69.
      70. Nightingale CH. A survey of the quality of generic clarithromycin products from 18 countries. Clin Drug Investig. 2005;25(2):135-52.
      71. Cammarota S, Bruzzese D, Sarnelli G, Citarella A, Menditto E, Riegler S, Savino IG, Vozzella L, Piccinocchi G, Napoli L, Arpino G, Cuomo R. Proton pump inhibitors prescribing following the introduction of generic drugs. Eur. J. Clin. Invest. 2012; 42(10): 1068-1078.
      72. Передерий В. Г., Чернявский В. В. Медико-экономическая эффективность различных схем лечения Нр-позитивных дуоденальных язв. Сучасна гастроентерол. 2004; 3(17):72-76.
      73. Самсонов А. А., Гречушников В. Б., Андреев Д. Н., Юренев Г. Л., Лежнева Ю. А., Маев И. В. Оценка фармакоэкономических показателей лечения пациентов с заболеваниями, ассоциированными с Helicobacter pylori. Тер архив. 2014;86(8):56-61.
     


    Full text is published :
    Maev I.V., Andreev D.N., Samsonov A.A., Valiev A.M. MODERN SCHEMES OF ERADICATION THERAPY OF INFECTION HELICOBACTER PYLORI: STRATEGY OF DIFFERENTIATED APPLICATION, EFFICIENCY AND SAFETY. Experimental and Clinical Gastroenterology Journal. 2017;140(04):103-110
    Read & Download full text

    1. First Moscow State Medical Univercity (Moscow, Russian Federation)
    2. Pirogov Russian National Research Medical University (Moscow, Russian Federation)
    3. FSAI The Scientific Center of Children’s Health (Moscow, Russian Federation)
    4. Morozov Pediatric Clinical Hospital of Moscow Healthcare Department (Moscow, Russian Federation)
    5. Moscow Clinical and Research Center (Moscow, Russian Federation)
    6. Children’s Clinical and Research Institute of Emergency surgery and Trauma (Moscow, Russian Federation)

    Keywords:children,confocal laser endomicroscopy,optical biopsy,histology,gastric,duodenum

    Abstract:Aim: to analyze the value of confocal laser endomicroscopy in diagnostics of gastric and duodenal mucosa changes in children. Patients and Methods: In the current study a total of 116 children aged from 3 to 18 years old undergo conventional endoscopy with confocal laser endomicroscopy supplemented with mucosal biopsy followed by traditional histology in the period from 2011 until 2014. To determine the prognostic value of the of probe based CLE in the evaluation of normal and pathological changes of the gastric and duodenal mucosa a comparison of results of optical biopsy with the data obtained during the standard histological examination were performed. Results: After results of probe-based CLE and traditional histology were comprised optical biopsy showed 83,7 %sensitivity and 87,5 %specificity to gastritis with Spearmen correlation 0,67 (р=0,001); 86,7 % sensitivity and 81,8 %specificity to duodenitis with Spearmen correlation 0,67(р=0,001). Conclusion: Confocal endomicroscopy may become one of the leading methods in pediatric gastroenterology since it allows the endoscopists to inspect the mucosa at the cellular level during the endoscopic procedure and can help to eliminate the mismatch between histological and endoscopic diagnosis.

      1. Бельмер С. В., Разумовский А. Ю., Хавкин А. И. (ред.). Болезни желудка и двенадцатиперстной кишки у детей - М.: ИД-МЕДПРАКТИКА-М, 2017, 536 с.
      2. Лазебник Л. Б., Щербаков П. Л. Гастроэнтерология. М.: Издание медицинских книг, 2011. -357с.
      3. Sheiko M. A., Feinstein J. A., Capocelli K. E., Kramer R. E. Diagnostic yield of EGD in children: a retrospective single-center study of 1000 cases.Gastrointestinal Endoscopy. 2013; Vol. 78(1), p. 47-54.
      4. Шавров А. А., Харитонова А. Ю., Шавров А. А., Морозов Д. А. Современные методы эндоскопической диагностики и лечения болезней верхнего отдела пищеварительного тракта у детей.Вопросы современной педиатрии. 2015. Т. 14. № 4. С. 497-502.
      5. Wallace M., Lauwers G. Y., Chen Y. Miami classification for probe-based confocal laser endomicroscopy. Endoscopy. 2011; 43(10):882-891.
      6. Dixon M. F., Genta R. M., Yardley J. H., Correa P. Classification and grading of gastritis. The updated Sydney System. Am. J. Surg. Pathol. 1996; 20:1161-1181.
      7. Gershman G., Thomson M. Practical Pediatric Gastrointestinal endoscopy, Second edition. Wiley-Blackwell; 2012. p. 256.
      8. Шавров (мл.) А.А., Шавров А. А., Харитонова А. Ю., Морозов Д. А., Талалаев А. Г., Гайдаенко А. Е., Калашникова Н. А. Конфокальная лазерная эндомикроскопия: история развития, проблемы и перспективы у детей. Вестник РАМН. 2014;11-12:60-66.
      9. Шавров (мл.) А.А., Волынец Г. В., Шавров А. А., Хавкин А. И., Талалаев А. Г., Хомерики С. Г., Харитонова А. Ю. Оптическая биопсия в диагностике изменений слизистой оболочки пищевода у детей. Экспериментальная и клиническая гастроэнтерология. 2015; 122 (10): 7-12.
      10. Greenson J., Polydorides A. D., Montgomery E. A., Lauwers G., Purdy J., Lamps L. Diagnostic Pathology: Gastrointestinal. Amirsys; 2009. p.800.
      11. Carr N. J., Leadbetter H., Marriott A. Correlation between the endoscopic and histologic diagnosis of gastritis. Ann. Diagn. Pathol. 2012; Vol. 16, p. 13-15.
      12. Oderda G, Forni M, Farina L, et al. Duodenitis in children: clinical, endoscopic, and pathological aspects. Gastrointestinal Endoscopy 1987; Vol. 33, p. 366-369.
     


    Full text is published :
    Shavrov A.A., Volynets G.V., Khavkin A.I., Morozov D.A. et al. CONFOCAL LASER ENDOMICROSCOPY FOR DIAGNOSIS OF GASTRIC AND DUODENAL MUCOSAL CHANGES IN CHILDREN. Experimental and Clinical Gastroenterology Journal. 2017;140(04):111-116
    Read & Download full text